Aduro BioTech

Type: Company
Name: Aduro BioTech
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma

On September 10, the Mesothelioma Applied Research Foundation (Meso Foundation) will interview Stephen Isaacs, the chairperson, president and CEO of Aduro BioTech, during a new installment of the Foundation’s Meet the Mesothelioma Experts live broadcast. ... [Published Bio-Medicine - Aug 28 2014]
First reported Jul 29 2014 - Updated Jul 30 2014 - 1 reports

Could a combination of two vaccines treat pancreatic cancer?

Researchers have developed a breakthrough therapy in the treatment of one of the world’s deadliest cancers: pancreatic cancer.Regulators designated Aduro Biotech Inc.'s new combination of CRS-207 and GVAX Pancreas drugs a "breakthrough therapy," putting ... [Published FOXNews.com - Jul 29 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Clinical Development News, July 21-25

The following is a list of clinical development news from private and public companies during the week of July 21-25. Private companies: Aduro BioTech Inc., Berkeley, Calif., said that the combination of CRS-207 and GVAX Pancreas ... ... [Published Dow Jones Financial Information Services - Jul 25 2014]
First reported Jul 21 2014 - Updated Jul 22 2014 - 2 reports

Aduro BioTech Receives FDA Breakthrough Therapy Designation for Innovative Pancreatic Cancer Combination Immunotherapy

Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its pancreatic cancer combination treatment that consists of its CRS-207 an ... [Published BioPortfolio - Jul 21 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 5 reports

Aduro BioTech Names Industry Veteran and Academic Leader, Gerald Chan, DSc to its Board of Directors

BERKELEY, Calif.--(EON: Enhanced Online News)--Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that renowned academic leader and industry veteran, Gerald Chan, DSc has joined its board of directors. Dr. Chan is the co-founder ... [Published EON Business - Jul 17 2014]
First reported Jun 13 2014 - Updated Jun 13 2014 - 1 reports

Aduro raises $55 million in series C financing

Aduro BioTech announced the closing of a $55 million Series C financing. New investor Johnson & Johnson Development joined the Morningside group and other new and existing investors in the transaction. Aduro plans to use the new capital to advance its ... [Published BioPortfolio - Jun 13 2014]
First reported Jun 11 2014 - Updated Jun 12 2014 - 4 reports

Aduro BioTech secures $55 mln Series C

Clinical stage biotechnology company Aduro BioTech has closed a $55 million Series C financing. New investor Johnson & Johnson Development Corporation joined the Morningside group and other new and existing investors in the transaction. PRESS RELEASE ... [Published PE Hub Blog - Jun 12 2014]
First reported Jun 02 2014 - Updated Jun 02 2014 - 1 reports

Aduro Announces ASCO Presentation of Promising Results from Phase 1b Clinical trial of its Novel Immunotherapy for the Treatment of Mesothelioma

CHICAGO & BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical stage biotechnology company, today announced the presentation of safety and efficacy data from a Phase 1b clinical trial of its novel immunotherapy CRS-207 in combination with ... [Published Business Wire Health News - Jun 02 2014]
First reported May 30 2014 - Updated May 31 2014 - 2 reports

Aduro inks agreement with Janssen Biotech for prostate cancer candidates

Aduro BioTech, a clinical-stage biotechnology company, has entered into an agreement granting Janssen Biotechan exclusive worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on its novel. ... [Published BioPortfolio - May 31 2014]
First reported May 29 2014 - Updated May 30 2014 - 5 reports

Aduro licenses immunotherapy products to Janssen

Aduro BioTech Inc. (Berkeley, Calif.) granted the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to products based on Aduro's live-attenuated double-deleted Listeria monocytogenes (LADD) immunotherapy plat ... [Published BioPortfolio - May 30 2014]
First reported May 20 2014 - Updated May 21 2014 - 1 reports

Aduro Announces Pancreatic Cancer and Mesothelioma Abstracts to Be Presented at 2014 ASCO Annual Meeting

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical stage biotechnology company, today announced that two posters highlighting clinical trials of the company’s pancreatic cancer and mesothelioma immunotherapies will be presented at the ... [Published Business Wire Health News - May 20 2014]
First reported May 05 2014 - Updated May 05 2014 - 3 reports

Aduro BioTech Announces Initation of a Clinical Trial of Its Novel Immunotherapy in Patients with Brain Cancer at Providence Cancer Center

BERKELEY, Calif.--(EON: Enhanced Online News)--Aduro BioTech, Inc., a clinical stage biotechnology company, today announced that the first patients have been enrolled in a Phase 1 clinical trial to evaluate its novel immunotherapy ADU-623 in patients ... [Published EON Science - May 05 2014]

Quotes

Aduro president and CEO Stephen Isaacs said: "We are extremely pleased to receive breakthrough therapy designation and the high degree of FDA collaboration toward advancement of our programme that it confers."
Original Article: NEXT ARTICLE More From BioPortfolio on "Aduro BioTech Receives FDA Breakthrough Therapy Designation for Innovative Pancreatic Cancer Combination Immunotherapy"
Original Article: NEXT ARTICLE More From BioPortfolio on "Aduro inks agreement with Janssen Biotech for prostate cancer candidates"
Original Article: NEXT ARTICLE More From BioPortfolio on "Janssen to expend up to $356 million for rights to Aduro Biotech prostate cancer technologies"

More Content

All (54) | News (11) | Reports (0) | Blogs (42) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
New Clinical Trial: Using the Listeria Virus to... [Published Bio-Medicine - Aug 28 2014]
Could a combination of two vaccines treat pancr... [Published FOXNews.com - Jul 29 2014]
Clinical Development News, July 21-25 [Published Dow Jones Financial Information Services - Jul 25 2014]
Aduro’s pancreatic cancer immunotherapy gets FD... [Published Pharmaceutical Technology - Jul 22 2014]
Aduro BioTech Receives FDA Breakthrough Therapy... [Published BioPortfolio - Jul 21 2014]
Aduro BioTech Receives Breakthrough Therapy Des... [Published Business Wire Health News - Jul 21 2014]
Aduro BioTech Names Industry Veteran and Academ... [Published EON Business - Jul 17 2014]
Aduro BioTech Names Industry Veteran and Academ... [Published EON Science - Jul 17 2014]
Aduro BioTech Names Industry Veteran and Academ... [Published Business Wire Science: Science News - Jul 17 2014]
Aduro BioTech Names Industry Veteran and Academ... [Published Business Wire Professional Services News - Jul 17 2014]
Aduro BioTech Names Industry Veteran and Academ... [Published Business Wire Health News - Jul 17 2014]
Aduro raises $55 million in series C financing [Published BioPortfolio - Jun 13 2014]
Aduro BioTech secures $55 mln Series C [Published PE Hub Blog - Jun 12 2014]
Aduro BioTech Secures $55 Million Series C Fina... [Published EON Science - Jun 11 2014]
Aduro BioTech Secures $55 Million Series C Fina... [Published Business Wire Science: Science News - Jun 11 2014]
Aduro BioTech Secures $55 Million Series C Fina... [Published Business Wire Health News - Jun 11 2014]
Aduro Announces ASCO Presentation of Promising ... [Published Business Wire Health News - Jun 02 2014]
Aduro inks agreement with Janssen Biotech for p... [Published BioPortfolio - May 31 2014]
Aduro signs a pharma deal with Janssen Biotech [Published BioPortfolio - May 30 2014]
Aduro licenses immunotherapy products to Janssen [Published BioPortfolio - May 30 2014]
Janssen to expend up to $356 million for rights... [Published BioPortfolio - May 30 2014]
Aduro Janssen enter license deal for new immuno... [Published BioPortfolio - May 30 2014]
Aduro, Janssen enter license deal for new immun... [Published PBR - News - May 30 2014]
Aduro Announces License Agreement with Johnson ... [Published Business Wire Health News - May 29 2014]
Aduro Announces Pancreatic Cancer and Mesotheli... [Published Business Wire Health News - May 20 2014]
Aduro BioTech Announces Initation of a Clinical... [Published EON Science - May 05 2014]
Aduro BioTech Announces Initation of a Clinical... [Published Business Wire Science: Science News - May 05 2014]
Aduro BioTech Announces Initation of a Clinical... [Published Business Wire Health News - May 05 2014]
BDP Week: Takeways from Day One [Published Future of BioPharma - Mar 25 2014]
BioNews – 02/10/14 [Published eClinical Trends - Feb 10 2014]
1 2
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Aduro BioTech Receives Breakthrough Therapy Des... [Published Business Wire Health News - Jul 21 2014]
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its pancreatic cancer combination treatment ...
Aduro BioTech Names Industry Veteran and Academ... [Published EON Business - Jul 17 2014]
BERKELEY, Calif.--(EON: Enhanced Online News)--Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that renowned academic leader and industry veteran, Gerald Chan, DSc has joined its board of directors. Dr. Chan is the co-founder ...
Aduro BioTech Names Industry Veteran and Academ... [Published EON Science - Jul 17 2014]
BERKELEY, Calif.--(EON: Enhanced Online News)--Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that renowned academic leader and industry veteran, Gerald Chan, DSc has joined its board of directors. Dr. Chan is the co-founder ...
Aduro BioTech Names Industry Veteran and Academ... [Published Business Wire Science: Science News - Jul 17 2014]
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that renowned academic leader and industry veteran, Gerald Chan, DSc has joined its board of directors. Dr. Chan is the co-founder of Morningside, ...
Aduro BioTech Names Industry Veteran and Academ... [Published Business Wire Professional Services News - Jul 17 2014]
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that renowned academic leader and industry veteran, Gerald Chan, DSc has joined its board of directors. Dr. Chan is the co-founder of Morningside, ...
1 2 3 4 5 6 7 8 9
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.